leadf
logo-loader
viewSynairgen PLC

Synairgen unveils positive data from phase II chronic obstructive pulmonary disease trial

Synairgen PLC's (LON:SNG) Richard Marsden talks to Proactive London's Katie Pilbeam after revealing positive data from their phase II study on people with chronic obstructive pulmonary disease (COPD).

Marsden explains that this data reveals that their inhaled interferon beta drug, which was used on older patients is firstly safe and also works towards Synairgen's COVID-19 programme.

For Synaigen, the focus is on Covid-19 and to progress with SNG001 as a therapeutic for the virus, which means the COPD programme will remain paused for now.

Quick facts: Synairgen PLC

Price: 172.51 GBX

AIM:SNG
Market: AIM
Market Cap: £344.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read